Table 5.
Comparison of changes in prevalence of treatment-emergent extrapyramidal symptoms and adjunctive use of medications between baseline and at endpoint
| Variables for extrapyramidal symptoms | Baseline | Endpoint | p value |
|---|---|---|---|
| Parkinsonian feature (≥ 2 of SAS total score) | 12 (15.6) | 9 (11.7) | 0.508 |
| Akathisia (≥ 2 of BAS global score) | 4 (5.2) | 3 (3.9) | 1.000 |
| Tardive dyskinesia (≥ 2 of AIMS any item) | 7 (9.1) | 4 (5.2) | 0.375 |
| Adjunctive use of anticholinergics | 61 (76.3) | 38 (47.5) | < 0.001 |
| Adjunctive use of propranolol | 35 (43.8) | 26 (32.5) | 0.064 |
| Adjunctive use of benzodiazepine | 34 (42.5) | 25 (31.3) | 0.064 |
Values are presented as number (%).
SAS, Simpson−Angus Scale; BAS, Barnes Akathisia Rating Scale; AIMS, Abnormal Involuntary Movement Scale.